Bulk Pharmaceutical API Sources for ORTHO-NOVUM 10-21

Bulk Pharmaceutical API Sources for ORTHO-NOVUM 10-21

Vendor	Vendor Homepage	Vendor Sku	API Url
BenchChem		B1200416
THE BioTek		bt-1540714
RR Scientific		R5270913

Bulk Active Pharmaceutical Ingredient (API) Sources for: ORTHO-NOVUM 10/21

Last updated: August 5, 2025

---

Introduction

Orthoe-Novum 10/21, a combined oral contraceptive containing ethinyl estradiol and norgestrel, relies on high-quality Active Pharmaceutical Ingredients (APIs) to ensure efficacy, safety, and regulatory compliance. Sourcing bulk APIs involves identifying manufacturers that meet strict quality standards, possess proven manufacturing capabilities, and comply with international guidelines such as USP, EP, or JP. This report provides an in-depth analysis of viable API sources for ethinyl estradiol and norgestrel, focusing on their manufacturing landscapes, regulatory statuses, and strategic considerations for pharmaceutical companies.

---

Overview of APIs in ORTHO-NOVUM 10/21

Ethinyl Estradiol: A synthetic estrogen derivative vital for ovulation suppression, its quality directly influences the contraceptive's effectiveness.

Norgestrel: A progestin that contributes to preventing ovulation and maintaining contraceptive stability.

Both APIs are complex molecules requiring advanced synthetic pathways, robust purification processes, and rigorous quality control.

---

API Sourcing Landscape for Ethinyl Estradiol

Global Production and Key Manufacturers

Ethinyl estradiol is synthesized predominantly in China, India, and select European countries. These regions host manufacturers with established track records, often approved by global regulators.

• Chinese Manufacturers
  Chinese API producers are prevalent, driven by cost competitiveness and scalable production capacities. Companies such as Hubei Tianxi Pharmaceutical, Sichuan Shuangou Pharmaceutical, and Hainan Esing Pharmaceutical are recognized for producing ethynyl estradiol complying with GMP standards. These firms often supply both branded and generic APIs, with some possessing WHO-GMP certification, enhancing exportability and regulatory acceptance.

• Indian Manufacturers
  India hosts prominent API manufacturers, including Lupin Limited, Sun Pharmaceutical Industries, and Aurobindo Pharma, with extensive experience in hormone APIs. Their facilities often meet global quality standards, and they possess multiple certifications (e.g., US FDA, EMA, WHO-GMP). The Indian API industry is known for its robust manufacturing infrastructure, consistent supply, and cost-efficient production.

• European and US-Based Manufacturers
  European API producers such as IDA Pharmer and BASF maintain high-quality standards, often catering to regulated markets. US-based manufacturers, while fewer in number, such as Sigma-Aldrich/Merck, supply research-grade and some pharmaceutical-grade APIs, often with advanced quality certifications.

Regulatory Considerations

API manufacturers must comply with Good Manufacturing Practices (GMP) and meet regulatory standards of target markets (FDA, EMA, PMDA). Many Chinese and Indian companies have achieved regulatory approvals, including US FDA inspection certifications, which are critical for global supply chains.

Supply Chain and Quality Assurance

Most reputable manufacturers maintain stability with supply commitments, quality assurance protocols, and extensive analytical testing. Exporters with WHO-GMP certification are preferable, as they facilitate smoother approval processes in importing countries.

---

API Sourcing Landscape for Norgestrel

Manufacturer Profiles

Norgestrel, as a synthetic progestin, is produced via complex chemical synthesis involving multiple steps, catalysts, and rigorous purification stages. The primary API manufacturers for norgestrel mirror those of ethinyl estradiol, predominantly located in China and India.

• Chinese Producers
  Firms like Hainan Esing Pharmaceutical and Zhuhai Microlife Pharmaceutical have established capabilities for norgestrel production aligned with international standards. Their products often undergo extensive analytical validation, including HPLC and residual solvent testing.

• Indian Producers
  Companies such as Suven Life Sciences, Aurobindo Pharma, and Cipla are recognized for manufacturing norgestrel APIs. Their facilities are often inspected by US FDA and EMA, with multiple regulatory approvals supporting their credibility.

• European and US Suppliers
  These suppliers tend to cater to high-end markets, offering APIs with superior purity profiles, certified for use in highly regulated markets.

Quality and Regulatory Compliance

Norgestrel manufacturing entities often adhere to stringent quality systems, employing comprehensive validation techniques to ensure batch consistency and impurity profile compliance.

---

Strategic Considerations for API Sourcing

1. Regulatory Compliance
   Prioritize API manufacturers with existing GMP certifications, especially WHO-GMP, US FDA, EMA, or TPD approvals, which streamline the approval process for drug marketing.

2. Supply Chain Stability
   Engage with manufacturers demonstrating reliable supply history, capacity to scale, and contingency planning to mitigate shortages.

3. Cost-Efficiency
   While cost remains a significant factor, quality and regulatory compliance should take precedence to prevent costly delays or failures in product approval and market entry.

4. Quality Assurance and Testing
   Perform comprehensive audits and analytical testing during qualification. Consider verification of residual solvents, stereochemistry, impurity profiles, and stability data.

5. Partnership and Long-term Agreements
   Cultivate strategic partnerships with reputable manufacturers for continuous, uninterrupted API supply.

---

Conclusion

Reliable API sources for ethinyl estradiol and norgestrel are crucial for manufacturing high-quality ORTHO-NOVUM 10/21 contraceptives. Indian and Chinese manufacturers dominate the landscape, with additional options available from European and US suppliers catering to highest regulatory standards. Selecting suitable API vendors requires balancing regulatory compliance, supply reliability, cost, and quality assurance.

---

Key Takeaways

• Global manufacturers in China and India are primary sources for bulk APIs due to their manufacturing capacity, cost advantage, and compliance track records.
• Regulatory certifications, particularly GMP approvals, are critical for reliable API sourcing, influencing approval timelines and market access.
• Supply chain robustness demands engagement with manufacturers demonstrating proven production stability and contingency planning.
• Quality assurance processes, including thorough analytical validation, are essential to verify API purity, stereochemistry, and impurity profiles.
• Long-term strategic partnerships with reputable API suppliers facilitate consistent supply, regulatory compliance, and market competitiveness.

---

FAQs

1. What certifications should I verify when sourcing APIs for ORTHO-NOVUM 10/21?
Verify GMP certifications, especially WHO-GMP, US FDA, or EMA approval, to ensure compliance with international manufacturing standards and facilitate regulatory approval.

2. Are Chinese API manufacturers reliable for high-quality APIs?
Many are reputable and possess rigorous quality systems, with some holding international certifications. Due diligence, including audits and analytical testing, remains essential.

3. How does cost impact API sourcing decisions for contraceptive manufacturing?
While cost considerations are significant, compromising on quality or regulatory compliance can lead to delays, rejection, or market withdrawal. Balance cost with quality and regulatory adherence.

4. Can APIs sourced from India and China be used interchangeably?
Yes, provided they meet the specified purity, stereochemistry, and impurity profiles, and are accompanied by valid quality certificates and regulatory approvals.

5. What role do API manufacturers play in mitigating supply chain disruptions?
Established manufacturers with diversified production sites and proven supply histories can mitigate risks associated with geopolitical issues, raw material shortages, or manufacturing disruptions.

---

Sources

1. WHO Global Database on Selected Medicines. (2022). API production sites.
2. US FDA Establishment GMP Inspection Reports. (2023).
3. Indian Pharmaceutical Industry Reports. (2022).
4. Chinese API Sector Analysis. (2022).
5. EMA Certified API Manufacturer Listings. (2023).